Medical specialists from France tagged as investigators in clinical trials studying Synovial Sarcoma

Total 3 results

Axel Le Cesne, MD
Seen in:
- Villejuif, Gustave Roussy
- Villejuif, Gustave Roussy Cancer Center
Trials:
- NCT04044768 (Principal Investigator)
- NCT04950075 (Principal Investigator)
Conditions:
Edouard Forcade, MD
Seen in:
- Pessac, Hospital Haut Leveque, CHU Bordeaux
Trials:
- NCT04044768 (Principal Investigator)
Conditions:
- Myxoid Liposarcoma;
- Synovial Sarcoma
Jean-Yves Blay, MD
Seen in:
- Lyon, Centre LEON BERARD
Trials:
- NCT04044768 (Principal Investigator)
- NCT04950075 (Principal Investigator)
- NCT02029001 (Principal Investigator)
- NCT04116541 (Principal Investigator)
- NCT05180695 (Principal Investigator)
Conditions:

Clinical Trials on Synovial Sarcoma

Foghorn Therapeutics Inc.

Terminated

FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors

Advanced Synovial Sarcoma

United States, Spain, France, Italy
OncoTherapy Science, Inc.

Terminated

Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma

Relapsed or Refractory Synovial Sarcoma

Japan
National Cancer Institute (NCI)

Completed

Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma

Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Adult Synovial Sarcoma

United States
C4 Therapeutics, Inc.

Terminated

A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

Soft Tissue Sarcoma | Synovial Sarcoma

United States
Immune Design

Terminated

A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

Sarcoma | Soft Tissue Sarcoma | Cancer | Synovial Sarcoma | Metastatic Sarcoma

United States, Canada
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Adult Liposarcoma | Adult Synovial Sarcoma

United States
GlaxoSmithKline

Completed

A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma (NY-ESO-1)

Neoplasms

United States
GlaxoSmithKline
Merck Sharp & Dohme LLC

Withdrawn

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

Neoplasms
Fred Hutchinson Cancer Center
Incyte Corporation

Active, not recruiting

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Refractory Soft Tissue Sarcoma | Metastatic Leiomyosarcoma | Metastatic Synovial Sarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Advanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Advanced Synovial Sarcoma | Metastatic Chondrosarcoma | Advanced Leiomyosarcoma | Metastatic Myxoid... and other conditions

United States
Children's Hospital of Philadelphia

Recruiting

Synovial Sarcoma Registry / Biospecimen Repository

Synovial Sarcoma

United States

Medical specialists from France tagged as investigators in clinical trials studying Synovial Sarcoma

Clinical Trials on Synovial Sarcoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations